(P18-021-24) Correlation of Metabolic Biomarkers on Moderate to High-Risk Weight-Gain Antipsychotic Medications on PLWH: A Miami Adult Studies for HIV (MASH) Cohort Study

Objectives: Guidelines for screening and monitoring antipsychotic-induced metabolic disturbances have been developed; however, they are not routinely implemented in clinical care. We investigated body mass index (BMI) and Waist Hip Ratio (WHR) among study participants who did or did not use antipsychotic medication in a minoritized population of virally suppressed Blacks and Hispanics living with HIV and participating in a Miami Adult Study for HIV (MASH) cohort.

Methods: Participants were interviewed by trained personnel for their socio-demographics, and anthropometrics. HIV positivity, antiretroviral and antipsychotic medications were abstracted from medical charts with participants’ written consent. Participants were categorized into two distinct groups based on whether they used or did not use antipsychotic medications, and those associated with moderate to high-risk for weight gain (amitriptyline, citalopram, mirtazapine, risperidone, quetiapine, or paroxetine.)

Results: A total of 143 participants were included in the study. The mean age was 52.8±7.07, with 60% males, 53% African Americans, and 36% Hispanics. Mean CD4 cell count was 626.97±367.18 cells/mm³ and HIV viral load was < 20 copies/dL. Out of the 143 participants, 62 did not take any antipsychotic medication and 81 were taking antipsychotic medication with moderate to high risk for weight gain. BMI and WHR were higher in group taking antipsychotic medication (R=0.64, P=0.001) among participants taking the antipsychotic medications compared to those who did not take the antipsychotic medications. The African Americans had higher BMI and WHR (R=0.92, p=0.001) than Caucasians. Men had higher WHR and BMI (R=0.74, P< 0.001) than women of all races and ethnicities.

Conclusions: While antipsychotic treatment is essential for mental health disorders, participants on active antiretroviral medication and moderate and/or high-risk weight gain antipsychotic medication should be followed, especially males, for metabolic disorders.

Funding Sources: Florida International University Research Clinic -Borinquen